TABLE 2

Outcomes after 1 year of treatment with anti-interleukin-5 biologics for severe asthma

nBaselinen1 yearp-value
Clinical outcomes
 Exacerbations in previous 12 months, n3913.08±3.13910.62±1.27<0.0001
 mOCS502187 (37)502123 (25)<0.0001
  Median dose, mg6310 (7.5–15)637.5 (5–10)<0.0001
 Budesonide-equivalent dose, µg2971600 (1600–2000)2971600 (1200–1600)<0.0001
 FEV1, L3652.25±0.853652.37±0.88<0.0001
 FEV1, % pred36269±2136274±21<0.0001
 FEV1/FVC3470.65±0.133470.66±0.120.0007
 FEV1 >80%362110 (30)362140 (39)0.0001
 ACQ score2422.49±1.31)2421.61±1.21<0.0001
 ACQ ≤1.524267 (28)242132 (55)<0.0001
Biomarkers
 Blood eosinophils, ×109 L−12800.31 (0.12–0.60)2820.06 (0.02–0.10)<0.0001
FENO, ppb28035 (18–65)28030 (16–59)0.01

Data are presented as mean±sd, n (%) or median (interquartile range), unless otherwise stated. mOCS: maintenance oral corticosteroids; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; FENO: exhaled nitric oxide fraction. Only patients with paired data at baseline and 12 months are included.